<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1547">
  <stage>Registered</stage>
  <submitdate>3/11/1994</submitdate>
  <approvaldate>3/11/1994</approvaldate>
  <actrnumber>ACTRN12606000534583</actrnumber>
  <trial_identification>
    <studytitle>IBCSG 11-93 - Adjuvant therapy for premenopausal patients with node positive breast cancer who are suitable for endocrine therapy alone</studytitle>
    <scientifictitle>Adjuvant therapy for premenopausal patients with node positive breast cancer who are suitable for endocrine therapy alone</scientifictitle>
    <utrn />
    <trialacronym>IBCSG 11-93</trialacronym>
    <secondaryid>National Clinical Trials Registry: NCTR19</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm A: Ovarian ablation and Tamoxifen (20mg orally daily) maintenance to 5 years
Arm B: Ovarian ablation + 4 cycles of Doxorubicin (60mg/m^2 iv) or epirubicin (90mg/m^2 iv) and cyclophosphamide (600mg/m^2 iv), followed by Tamoxifen (20mg orally daily) maintenance to 5 years.

Ovarian ablation can use any of the following methods:
* bilateral surgical oophorectomy via laparatomy or laparascopy OR
* bilateral ovarian irradiation OR
* GnRH (gonadotropin releasing hormone) analogue 3.6mg every 28 days continued for 2 years or until the patient is 55 years old, whichever is longer.  Note: ovarian ablation initiated with GnRH analogue may be continued by oophorectomy or radiation therapy.
Chemotherapy (21 day cycles) should start immediately after the ovarian ablation procedure or at day 1 of GnRH(gonadotropin releasing hormone) analogue administration; within 6 weeks of primary surgery.</interventions>
    <comparator>Please see "Description of interventions" above. Study completed recruitment in 1998.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>Patients are followed at each chemotherapy cycle and 3 monthly in the first year, 6 monthly years 2-5 and yearly thereafter for life.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Disease-free and systemic disease-free survival</outcome>
      <timepoint>Patients are followed at each chemotherapy cycle and 3 monthly in the first year, 6 monthly years 2-5 and yearly thereafter for life.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life</outcome>
      <timepoint>Assessed 3 monthly in the first year, 6 monthly in year 2 and annually thereafter to year 6.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Toxicity</outcome>
      <timepoint>Assessed at the conclusion of each cycle of treatment up to 30 days after the last dose date.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria> Premenopausal women with histologically proven primary breast cancer Positive lymph nodes (metastases detected in 1 or more of at least 8 ipsilateral axillary nodes examined). The primary tumour must be classified as T1a,b,c T2 or T3, pN1, M0 (UICC 1987) Patients must be judged suitable for treatment with endocrine therapy alone. As a minimum, must have ER positive tumours (ER&gt;= 10 fmol/mg cytosol protein) or PR positive tumours (PgR&gt;= 10 fmol/my cytosol protein) Patients must have had:a) Either total mastectomy or, optionally if the tumour is &lt;=5cm, breast-conserving procedure (lumpectomy or quadrantectomy)b) Axillary clearance with at least eight lymph nodes available for pathological examinationc) The primary breast cancer surgical procedure must be within 6 weeks prior to randomisation Minimum of 8 lymph nodes histopathologically examined with at least one found positive Tumour must be confined to breast without detected metastases Adequate marrow function (WBC &gt;= 4.0 x 10^9/L and platelet count &gt;= 100 x 10^9/L) Adequate renal function (serum creatinine &lt; 120 umol/L) and hepatic function (serum bilirubin &lt; 20umol/L, AST (SGOT) &lt; 60 i.u./L) Informed consent Geographically accessible for follow-up</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria> Patients without axillary node involvement Malignant breast tumours other than carcinoma T4 carcinoma with ulceration, infiltration of skin, peau d'orange or inflammatory breast cancer Bilateral malignancies, or mass in opposite breast Margins of resected specimen contained tumour cells ER- and PR- tumours Previous or concomitant other malignancy except basal or squamous cell carcinoma of skin or in situ carcinoma of cervix Prior therapy for breast cancer Non-malignant systemic diseases preventing treatment options or follow-up Psychiatric or addictive disorders preventing informed consent Bone scans showing hot spots which cannot be confirmed as benign disease Pregnant or lactating</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central Randomisation by Telephone</concealment>
    <sequence>Computer generated stratified blocks</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>N/A</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/05/1993</anticipatedstartdate>
    <actualstartdate>15/07/1993</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/11/1998</actualenddate>
    <samplesize>760</samplesize>
    <actualsamplesize>174</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>International Breast Cancer Study Group</primarysponsorname>
    <primarysponsoraddress>Effingerstrasse 40, 3008 Bern</primarysponsoraddress>
    <primarysponsorcountry>Switzerland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Australia and New Zealand Breast Cancer Trials Group</fundingname>
      <fundingaddress>PO BOX 155
HRMC NSW 2310</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Australia and New Zealand Breast Cancer Trials Group</sponsorname>
      <sponsoraddress>PO BOX 155
HRMC NSW 2310</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial involves premenopausal women who after surgery for their breast cancer are found to have tumours which are hormone receptor positive (stimulated  by hormones) and who also have positive axillary lymph nodes (glands under the arm pit containing cancer). For these women it is not known whether hormonal treatment alone is sufficient, or whether the addition of chemotherapy may be beneficial in reducing the incidence of disease recurrence and improving survival.

Women who take part in this trial will all have their ovarian function suppressed and receive Tamoxifen. In addition, patients may or may not receive chemotherapy.</summary>
    <trialwebsite />
    <publication>N/A</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Dubbo Base Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Liverpool Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Newcastle Mater Misericordiae Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>1/05/1993</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bendigo Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Geelong Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Melbourne Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincent's Hospital, Melbourne</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Western Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Auckland Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Waikato Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>John F Forbes</name>
      <address>ANZBCTG
PO BOX 155
HRMC NSW 2310</address>
      <phone>+ 61 2 4985 0113</phone>
      <fax>+ 61 2 4960 1539</fax>
      <email>enquiries@anzbctg.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Corinna Beckmore</name>
      <address>ANZBCTG
PO BOX 155
HRMC NSW 2310</address>
      <phone>+61 2 4985 0159</phone>
      <fax>+61 2 4985 0141</fax>
      <email>enquiries@anzbctg.org</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>John F Forbes</name>
      <address>ANZBCTG
PO BOX 155
HRMC NSW 2310</address>
      <phone>+61 2 4985 0113</phone>
      <fax />
      <email>enquiries@anzbctg.org</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>